You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,637,554


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,637,554
Title:Methods for treating thyroid cancer
Abstract: The invention provides methods for enhancing iodine absorption in a thyroid in a subject and treating thyroid cancer by administering to the subject a composition which includes a multi-kinase inhibitor. Furthermore, the invention provides methods for improving a medical diagnostic procedure based on radioactive iodine in a subject by administering to the subject a composition comprising a multi-kinase inhibitor.
Inventor(s): Brose; Marcia S. (Bryn Mawr, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:12/436,957
Patent Claims:1. A method of treating a thyroid cancer in a subject, comprising the step of enhancing iodine absorption in a thyroid in said subject by administering to said subject a composition comprising sorafenib and an mTOR inhibitor, and whereby said mTOR inhibitor is everolimus, tacrolimus, ABT-578, AP-23675, AP-23573, AP-23841, or combinations thereof, thereby treating said thyroid cancer in said subject.

2. The method of claim 1, whereby said thyroid cancer is differentiated metastatic thyroid cancer.

3. The method of claim 2, whereby said differentiated metastatic thyroid cancer is follicular or papillary differentiated metastatic thyroid cancer.

4. The method of claim 2, whereby the metastatic thyroid cancer is a remote metastatic thyroid cancer.

5. The method of claim 1, whereby the composition is administered after a primary thyroid cancer treatment.

6. The method of claim 5, whereby the primary thyroid cancer treatment is a radioactive iodine therapy.

7. The method of claim 5, whereby the primary thyroid cancer treatment comprises a surgery.

8. The method of claim 1, whereby the composition is administered before a thyroid cancer treatment.

9. The method of claim 8, whereby the thyroid cancer treatment is a radioactive iodine therapy.

10. The method of claim 8, whereby the thyroid cancer treatment comprises a surgery.

11. The method of claim 1, whereby said composition reverses the differentiation process of a cell in said thyroid and enhances said cell's ability to absorb iodine.

12. The method of claim 1, wherein said composition further comprises radioactive iodine.

13. The method of claim 12, whereby said radioactive iodine is .sup.131I, .sup.123I, .sup.124I, .sup.125I, .sup.129I, or any combination thereof.

14. The method of claim 12, whereby the composition further comprises rosiglitazone.

15. The method of claim 12, whereby the composition further comprises one or more agents in addition to sorafenib and radioactive iodine.

16. The method of claim 15, whereby the agent is Sunitinib, Tanespimycin, KOS-953, 17-AAG, bortezomib, Vandetanib, Romidepsin, a histone deacetylase inhibitor, depsipeptide, gefitinib, irinotecan, AG-013736, lenalidomide, Belinostat, PXD101 or their combination.

17. The method of claim 15, whereby the agent inhibits VEGF-2, PDGF-.alpha., PDGF-.beta., FLT-3, or c-KIT, and whereby the agent is selected from the group consisting of Bevacizumab, Imatinib, Leflunomide, Midostaurin, Semaxanib, Vatalanib, Recentin, AG013736, CDP860, CP547,632, CP673,451, RPI 4610, SU6668, VEGF-trap, ZD6474, YM359445, and combinations thereof.

18. The method of claim 12, whereby the agent inhibits the RAF/MEK/ERK pathway, and whereby the agent is CI-1040, ISIS 5132, or a combination thereof.

19. A method for providing a medical diagnostic or therapeutic procedure based on radioactive iodine in a subject, comprising the steps of: administering to said subject a composition comprising sorafenib, and performing a medical diagnostic or a therapeutic procedure on said subject, comprising administering to said subject said radioactive iodine concurrently with or subsequently to administration of said composition comprising sorafenib, wherein the medical diagnostic or therapeutic procedure based on radioactive iodine is used for the treatment or diagnosis of a bulky disease selected from the group consisting of non-Hodgkin's Lymphoma, a prostate adenocarcinoma, a breast cancer, and a liver cancer.

20. The method of claim 19, whereby said medical diagnostic procedure is a whole body scans (WBS).

21. The method of claim 19, whereby said composition comprising sorafenib further comprises said radioactive iodine.

22. The method of claim 21, whereby said radioactive iodine is .sup.131I, .sup.123I, .sup.124I, .sup.125I, .sup.129I or any combination thereof.

23. The method of claim 19, whereby the composition further comprises one or more agents in addition to sorafenib.

24. The method of claim 23, whereby the agent is Sunitinib, Tanespimycin, KOS-953, 17-AAG, bortezomib, Vandetanib, Romidepsin, Rosiglitazone, a histone deacetylase inhibitor, depsipeptide, gefitinib, irinotecan, AG-013736, lenalidomide, Belinostat, PXD101 or their combination.

25. The method of claim 19, whereby the therapeutic procedure is radiotherapy, or radioimmunotherapy (RIT).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.